Join
Live feed
·
PRReleasevia Quantisnow
Senti Biosciences Inc. logo

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

ByQuantisnow·Wall Street's wire, on your screen.
SNTI· Senti Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNTI (Senti Biosciences Inc.) and more on Quantisnow.